Bedfont Scientific Limited has created a subsidiary, NoxBOX Limited, to concentrate on its successful range of Inhaled Nitric Oxide monitoring systems.
The new company has been created as part of Bedfont’s long-term development and expansion plans.
Established in 1976 in Kent, UK, Bedfont specialises in exhaled breath and gas monitors for the medical industry. The NOxBOX range was introduced by Bedfont in 1992 and is used to deliver and monitor inhaled nitric oxide (iNO) therapy.
iNO therapy is mainly used in intensive care units (ICU) to aid in the therapeutic care of premature babies and patients under severe respiratory distress. Using iNO therapy allows the blood supply to pick up oxygen from the lungs more readily by dilating the pulmonary arteries, making it the ideal method of treatment for pulmonary hypertension and other conditions that can lead to severe breathing difficulties.
“Our aim for NOxBOX Limited is to grow the customer base globally, continuing to save lives, one breath at a time…”
Now, Bedfont has established the whole NoxBOX subsidiary dedicated to this technology front, focusing on increasing awareness of the NOxBOX product and associated healthcare benefits to improve market share in the UK and Europe. It also aims to further develop the customer base across the global market, while parent company Bedfont Scientific will concentrate on developing new products and increasing use of its wide range of existing breath and gas monitoring systems.
Jason Smith, Bedfont Scientific’s General Manager, said, “The success of the NOxBOX range has led us to what we feel is a natural progression that will further ensure the continued high levels of quality and service for our customers.”
“Our aim for NOxBOX Limited is to grow the customer base globally, continuing to save lives, one breath at a time.”